Adverse event totals12

The totals the trial posted for each group.

1 to 12 of 12

Total	Group	Affected	At risk
Total, all-cause mortality	210 mg Brodalumab
Total, all-cause mortality	140 mg Brodalumab
Total, all-cause mortality	Ustekinumab
Total, all-cause mortality	Placebo
Total, other adverse events	210 mg Brodalumab	354	612
Total, other adverse events	140 mg Brodalumab	365	610
Total, other adverse events	Ustekinumab	177	300
Total, other adverse events	Placebo	165	309
Total, serious adverse events	210 mg Brodalumab	6	612
Total, serious adverse events	140 mg Brodalumab	13	610
Total, serious adverse events	Ustekinumab	4	300
Total, serious adverse events	Placebo	8	309

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01708603/event-totals